Vaccines for Emerging Infectious Diseases Report 2018: Funding, R&D, and Global Partnership Strategies - ResearchAndMarkets.com

January 11, 2019

DUBLIN--(BUSINESS WIRE)--Jan 11, 2019--The “Vaccines for Emerging Infectious Diseases: Funding, R&D, and Global Partnership Strategies” report has been added to ResearchAndMarkets.com’s offering.

“Vaccines for Emerging Infectious Diseases: Funding, R&D, and Global Partnership Strategies” finds that philanthropic organizations and public-private partnerships like the Coalition for Epidemic Preparedness Innovations (CEPI) are filling a niche for funding translational and clinical vaccine research, allowing development of vaccines for diseases such as Lassa fever to occur even in the absence of an ongoing epidemic. As of November 2018, there were 235 vaccines in preclinical investigation, clinical development, or marketed for twelve major EIDs*.

Major EIDs include Zika, Ebola, MERS, Lassa, Marburg, Severe Acute Respiratory Syndrome (SARS), Chikungunya, CCHF, West Nile, Dengue, Yellow Fever, H5N1.

This report covers current and future challenges for the development and deployment of vaccines for EIDs, focusing on vaccine platform technology and research, funding mechanisms, and collaborative global partnerships.

Key Topics Covered:

1. Preface

2. Executive Summary

Key Findings KOL Insights on Vaccines for Emerging Infectious Diseases

3. Overview of Emerging Infectious Diseases

Defining Emerging Infectious Diseases (EIDs) Drivers of Emerging Infections & Routes of Transmission Key EIDs Ebola Virus Disease Zika Virus Disease Middle East Respiratory Syndrome (MERS) and Other EIDs

4. Clinical Trial Design

Clinical Trial Design Challenges Randomization Units Selection of Clinical Trial Population and Comparator Additional Strategies for Vaccine Approvals Unmet Needs in Clinical Trial Design

5. Vaccine Platform Technologies

Overview of Vaccine Platform Technologies Vaccine Platforms By Stage of Development Live-attenuated Vaccines Viral Vector-Based Vaccines DNA Vaccines Whole-Inactivated Vaccines, Subunit Vaccines, and VLPs

6. Funding and Market Incentives

Funding Sources for Vaccines for EIDs Push and Pull Incentives Challenges for Funding of Vaccine Development Lessons from the Ebola and Zika Outbreaks

7. Global Collaborations for Vaccine Development

Global Vaccine Development Fund and Priority Diseases Coalition for Epidemic Preparedness Innovations (CEPI) Vaccine Preparedness Global Virome Project (GVP) and Other Public-Private Partnerships

8. Pipeline Vaccines for Key Emerging Infectious Diseases

Clinical Development of Vaccines for EIDs Ebola Vaccine Pipeline Zika Vaccine Pipeline MERS-CoV Vaccine Pipeline

9. Surveillance and Healthcare Infrastructures

Disease Surveillance for EIDs Logistical Challenges for Vaccine Delivery Vaccine Preparedness Unmet Needs in Basic Vaccine Research

Companies Mentioned

Bharat Biotech Emergent Biosolution IDT Biologika Imutex Inovio Integrated Biotherapeutics Johnson & Johnson/Janssen GeneOne Life Science GlaxoSmithKline NewLink Genetics Merck Novartis Novavax Pfizer Profectus

For more information about this report visit https://www.researchandmarkets.com/research/zhwzpx/vaccines_for?w=4

View source version on businesswire.com:https://www.businesswire.com/news/home/20190111005139/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager


For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Infectious Disease Testing,Vaccines



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 01/11/2019 06:26 AM/DISC: 01/11/2019 06:27 AM


Update hourly